Introduction {#s1}
============

The viridans group streptococci (VGS) are a heterogeneous group of gram positive cocci, which form part of the normal human flora of the oral cavity, respiratory, urogenital, and gastrointestinal tracts (Spellberg and Brandt, [@B28]). Currently, VGS is subdivided into six major groups: *S. anginosus, S. bovis, S. mitis, S. mutans, S. salivarius*, and *S. sanguinis* (Facklam, [@B8]; Doern and Burnham, [@B6]). Accurate identification of species within the VGS group is important for assessing the clinical significance of the organism and to facilitate appropriate antimicrobial therapy (Sinner and Tunkel, [@B27]; Doern and Burnham, [@B6]). However, due to constant taxonomic changes in the VGS group, identification of species is challenging. No phenotypic identification method can be used as a gold standard for VGS as most methods, including API Strep, and Vitek 2, have only 30--80% identification accuracy, depending on the species (Ikryannikova et al., [@B12]; Teles et al., [@B30]).

Sequence analysis targeting different single genes such as 16S rRNA gene, *rpoA, rpoB, rnpB, rodA, soda*, and *gdh*, have been used in the identification of VGS species with various degrees of success (Poyart et al., [@B23]; Ip et al., [@B13]; Westling et al., [@B33]; Konishi et al., [@B17]; Nielsen et al., [@B21]; Park et al., [@B22]). Currently, only multilocus sequence analysis (MLSA) can accurately and reliably identify species within the VGS group. But MLSA is too expensive and laborious for routine laboratory diagnostic use (Bishop et al., [@B3]). Recently, Galloway-Peña et al. reported that the *gyrB* amino acid sequence may offer a more practical and accurate method for speciating invasive VGS strains than MLSA (Galloway-Pena et al., [@B9]).

In recent years, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) has emerged as a rapid and cost-effective alternative assay for bacterial identification (Seng et al., [@B26]; Bizzini et al., [@B4]; Neville et al., [@B20]). Nevertheless, some studies indicate that this assay has problems in distinguishing species within the *S. mitis* group (Ikryannikova et al., [@B12]; Davies et al., [@B5]; Wessels et al., [@B32]).

We investigated the performance of two MALDI-TOF MS systems, namely Bruker Biotyper (Daltonics, German) and Vitek MS (bioMérieux, France) in the identification of species within the VGS group, using sequencing of the 16S rRNA, and *gyrB* genes as a gold standard.

Materials and methods {#s2}
=====================

Bacterial strains and cultures
------------------------------

Clinically significant VGS isolates (*n* = 181) from sputum (*n* = 81), blood cultures (*n* = 29), tracheal aspirates (*n* = 11), midstream urine (*n* = 9), and other various sterile and non-sterile sites (*n* = 51) from Peking Union Medical College Hospital (PUMCH; 2013--2014), were studied (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Initial identification of these isolates was done by conventional methods (positive Gram stain, coccus morphology in chains, alpha-hemolysis, and a negative catalase test) and Vitek 2 compact system. Optochin and bile solubility tests were performed to differentiate pneumococci from non-pneumococci. The isolates were stored at −70°C in skim milk until further testing.

Gene sequencing-based identification
------------------------------------

Template DNA was prepared as described by. Dubois et al. ([@B7]). The16S rRNA gene was amplified for all the isolates using the universal primers 27F 5′-AGAGTTTGATCMTGGCTCAG-3′ and 1492R 5′-TACGGYTACCTTGTT ACGACTT-3′ (Seng et al., [@B26]). Purified PCR products and sequencing primers (the same as for amplification) were mixed and sent to Ruibiotech (Beijing, China) for sequencing. Species identification was performed by comparing the obtained sequences against those in the GenBank database using BLASTn ([www.ncbi.nlm.nih.gov/blast](http://www.ncbi.nlm.nih.gov/blast)). A sequence similarity of 99% was applied as species identification "cut-off" value for the 16S rRNA gene region. Amplification and sequencing of the *gyrB* gene encoding DNA Gyrase subunit B was performed for all the non-pneumococci using primers gyrB7F 5′-GAAGTDGTIAARATYACBAAY CG-3′ and gyrB5R 5′-ACATCDGCATCRGTCAT-3′ (Maeda et al., [@B19]). Both the *gyrB* nucleotide and amino acid sequences were analyzed through BLASTn and BLASTp and a nucleotide sequence similarity of 96% or a signature amino acid at a certain position was applied as species identification standard according to Galloway-Pena et al. ([@B9]). Besides, the phylogenetic trees were generated based on 16S rRNA gene and *gyrB* gene. The region used for phylogenetic analyses and species identification was nucleotides 86--1336 for 16S rRNA gene and nucleotides 1113--1512, corresponding to amino acids 371--503 for *gyrB* gene respectively. Following alignment with Clustal W, the sequences were analyzed in MEGA version 5.2 to create radial trees using the neighbor-joining statistical method and the maximum likelihood composite model.

MALDI-TOF analysis
------------------

Two MALDI-TOF MS systems, Bruker Biotyper and Vitek MS, including both the *In Vitro* Diagnosis (IVD) and Research Use Only (RUO) modes were used to identify the 181 VGS isolates, according to the manufacturer\'s instructions. For both MALDI-TOF MS systems, direct transfer method were used for sample preparation. A small portion of a single colony after 24 or 48 h of incubation was smeared onto a target plate using a wooden cocktail stick, and covered with 1 μl matrix solution (α- cyano-4-hydroxycinnamic acid in 50 acetonitrile/2.5% trifluoroacetic acid, Bruker Daltonics, Bremen, Germany; α-cyano-4-hydroxycinnamic acid, VITEK® MS CHCA) immediately. For Bruker Biotyper, measurements were performed with the Bruker Biotyper MALDI-TOF MS system using FlexControl software with Compass Flex Series version 1.3 software and a 60-Hz nitrogen laser (337 nm wavelength). Spectra ranging from 2000 to 20,000 m/z were analyzed using the MALDI Biotyper system\'s automation control and the current Bruker Biotyper V.3.3.1.2 software and library \[database (DB) 5989 with 5989 entries\]. For Vitek MS, measurement was performed using the manufacturer\'s suggested settings using automated collecting spectra. Captured spectra (mass range of 2--20 kDa in the linear mode) were analyzed using the MALDI-TOF MS IVD MYLA database v2.0 and also the MALDI-TOF MS RUOsystem with the SARAMIS™ database v4.10 of bioMérieux. All identifications displaying a single result with a confidence score ≥1.7 or a confidence value of 99.9% were considered acceptable for Bruker Biotyper MS and Vitek MS, respectively (Karpanoja et al., [@B15]). For both MS systems, all isolates yielding a single result without acceptable confidence level or multiple results or "no identification" results were re-tested. If a single, species-level identification was obtained upon repeat analysis, this identification was considered to be the final MS result; otherwise no further analysis was performed.

Statistical analysis
--------------------

Agreement and validity values were calculated with a 95% confidence interval (CI) based on an exact binomial distribution. Data were analyzed using SPSS, version 15.0 (SPSS Inc, Chicago, IL, USA).

Results {#s3}
=======

The 16S rRNA gene and *GyrB* gene sequencing-based identification
-----------------------------------------------------------------

Using a combination of 16S rRNA gene and *gyrB* gene sequencing, all the 181 VGS isolates were assigned to species level on the basis of a ≥99 and ≥96% gene sequence similarity with published sequences in the GenBank. The DNA sequences of the16S rRNA gene and *gyrB* gene of the 181 VGS isolates studied have been submitted to GenBank database (accession numbers of [KX661043](KX661043)--[KX661223](KX661223) for 16S rRNA gene and [KX661224](KX661224)--[KX661319](KX661319) for *gyrB* gene respectively (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). Figure [1](#F1){ref-type="fig"} shows the phylogenetic trees generated by *gyrB* gene and 16S rRNA gene. As is shown in Figure [1A](#F1){ref-type="fig"}, *gyrB* nucleotide sequence successfully delineated all of the 96 non-pneumococci strains into individual species branches while in Figure [1B](#F1){ref-type="fig"}, all of the *S. oralis* isolates were branched with *S. mitis* isolates by 16S rRNA sequences. Besides, the bootstrap values between the mitis group were rather low compared to *gyrB* gene, which emphasizs the difficulties of using 16S gene sequences to correctly assign VGS strains to particular species. The identification results of the 181 VGS isolates are summarized in Supplementary Tables [S3](#SM3){ref-type="supplementary-material"}, [S4](#SM4){ref-type="supplementary-material"}, and [S5](#SM5){ref-type="supplementary-material"}, using gene sequencing as the gold standard.

![**Phylogenetic analyses using 16S rRNA and gyrB fragment sequences. (A)** Phylogenetic analysis using the gyrB sequence from nucleotides 1113--1512. **(B)** Phylogenetic analysis using the 16S rRNA sequence from nucleotides 86 to 1336.](fmicb-07-01328-g0001){#F1}

A high level of similarity in the 16S rRNA gene sequences of *S. pneumoniae, S. pseudopneumoni*ae, *S. mitis*, and *S. oralis*, which could make it difficult in distinguishing these species, has been reported (Kawamura et al., [@B16]; Arbique et al., [@B2]; Suzuki et al., [@B29]; Haanpera et al., [@B10]). Nevertheless, a recent study by Scholz et al. demonstrated that *S. pneumoniae* has a cytosine at position 203 of the 16S rRNA gene, while all other mitis group streptococci have adenine in that position (Scholz et al., [@B25]). In this study, we also checked position 203 of the 16S rRNA gene sequences, and confirmed that 85 isolates were pneumococci and the other 96 isolates non-pneumococci.

MALDI-TOF analysis
------------------

Compared to the gold standard, the Bruker Biotyper system correctly identified 88.4% (160/181) of the isolates to species level and misidentified 11.6% (21/181) of the isolates. This system performed poorly in the identification of species in the mitis group, correctly identifying 80.4% (86/107) of the isolates to species level and misidentifying 19.6% (21/107) of the isolates. Optochin tests were performed on all isolates with an identification result of *S. pneumoniae* in an atmosphere of 5% CO~2~, among which 85 isolates were sensitive and the other 21 were resistant. Specifically, 100 (11/11), 100 (2/2), and 88.9% (8/9) of *S. mitis, S. oralis*, and *S. pseudopneumoniae* isolates were misidentified as *S. pneumoniae*, respectively. For all other groups, the Bruker Biotyper system performed excellently, accurately identifying all the species within each of the respective groups. Furthermore, the system did not yield an invalid or "no identification result" on any isolates (Supplementary Table [S3](#SM3){ref-type="supplementary-material"}).

Vitek MS IVD correctly identified 98.9 (179/181) of the VGS isolates to species level, 0.55 (1/181) to group level, and 0.55% (1/181) with no identification. In contrast to the Bruker MS system which performed dismally in the identification of *S. pseudopneumoniae* isolates, the Vitek MS IVD correctly identified the majority (8 of 9, 88.9%) of these isolates to species level and the remaining one isolate to group level (Supplementary Table [S4](#SM4){ref-type="supplementary-material"}). Furthermore, the Vitek MS IVD gave a "no identification" result on one isolate within the bovis group (*S. gallolyticus*).

In comparison to Bruker Biotyper and Vitek MS IVD, the Vitek MS RUO system performed very poorly in VGS identification, with an overall correct species level, group level, and genus level identification rate of 38.7 (70/181), 42.0 (76/181), and 7.2% (13/181) respectively (Supplementary Table [S5](#SM5){ref-type="supplementary-material"}). The system especially performed poorly in identifying species within the mitis and bovis groups, with only 15.9 (17/107) and 25% (2/8) of the isolates correctly identified, albeit low number of isolates. In addition, 8.8 (16/181) and 3.3% (6/181) of the isolates studied were misidentified and yielded a "no identification" result, respectively.

Three MALDI-TOF systems comparisons
-----------------------------------

Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the three databases are shown in Table [1](#T1){ref-type="table"}. Overall, Bruker Biotyper gave a 100% sensitivity for the majority of the species identified, except for the mitis group species, namely *S. mitis* (0%), *S. oralis* (0%), and *S. pseudopneumoniae* (11.1%), most of which were misidentified as *S. pneumoniae* (21 of 22, 95.6%). Furthermore, PPV was incalculable for *S. mitis* and *S. oralis* as none of these isolates were correctly identified by the Bruker Biotyper. In contrast to other species in the mitis group, *S. pneumoniae*, had a 100% (95 CI: 95.8--100.0%) sensitivity and a 100% (95 CI: 95.5--100.0%) NPV, while the specificity and PPV were relatively low, at 78.1% (95 CI:68.5--85.9%) and 80.2% (95 CI:71.3%--87.3%), respectively.

###### 

**Identification performance comparison of three MALDI-TOF MS systems for each group of viridans group streptococci (VGS)**.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                         **No. (%) of isolate**   **Bruker Biotyper MS system**   **Vitek MS IVD system**   **Vitek MS RUO system**                                                                                                                                                         
  ---------------------- ------------------------ ------------------------------- ------------------------- ------------------------- ------------------ ------------------ ----------------- ----------------- ------------------ ------------------ ------------------ ------------------ ------------------
  **Mitis group**        **107**                  **80.4**\                       **71.6**\                 **80.4**\                 **71.6**\          **98.1**\          **98.7**\         **99.1**\         **97.3**\          **15.0**\          **33.8**\          **24.6**\          **21.6**\
                                                  **(71.6--87.4)**                **(60.0--81.5)**          **(71.6--87.4)**          **(60.0--81.5)**   **(93.4--99.8)**   **(92.7--100)**   **(94.9--100)**   **(90.7--99.7)**   **(8.8--23.1)**    **(23.2--45.7)**   **(14.8--36.9)**   **(14.6--30.2)**

  *S. mitis*             11                       0.0\                            100\                      IC                        93.9\              100\               99.4\             92.9\             100\               0.0\               95.3\              0.0\               93.6\
                                                  (0.0--28.5)                     (97.9--100)                                         (89.4--96.9)       (75.3--100)        (96.7--100)       (66.1--99.8)      (97.8--100)        (0.0--28.5)        (90.9--98.0)       (0.0--36.9)        (88.9--96.8)

  *S. oralis*            2                        0.0\                            100\                      IC                        98.9\              100\               99.4\             92.9\             100\               0.0\               91.6\              0.0\               98.8\
                                                  (0.0--84.2)                     (98.0--100)                                         (96.1--99.9)       (75.3--100)        (96.7--100)       (66.1--99.8)      (97.8--100)        (0.0--84.2)        (86.6--95.2)       (0.0--21.8)        (95.7--99.9)

  *S.pseudopneumoniae*   9                        11.1\                           100\                      100\                      95.6\              77.8\              100\              100\              98.9\              0.0\               95.9\              0.0\               94.8\
                                                  (0.3--48.3)                     (97.9--100)               (2.5--100)                (92.6--98.6)       (40.0--97.2)       (97.9--100)       (59.0--100)       (95.9--99.9)       (0.0--33.6)        (91.8--98.4)       (0.0--41.0)        (90.4--97.6)

  *S. pneumoniae*        85                       100\                            78.1\                     80.2\                     100\               100\               100\              100\              100\               18.8\              80.2\              45.7\              52.7\
                                                  (95.8--100)                     (68.5--85.9)              (71.3--87.3)              (95.2--100)        (95.8--100)        (96.2--100)       (95.8--100)       (96.2--100)        (11.2--28.8)       (70.8--87.6)       (28.8--63.4)       (44.3--61.1)

  **Anginosus group**    **52**                   **100**\                        **100**\                  **100**\                  **100**\           **100**\           **100**\          **100**\          **100**\           **93.1**\          **89.9**\          **74.5**\          **89.2**\
                                                  **(93.2--100)**                 **(97.2--100)**           **(93.2--100)**           **(97.2--100)**    **(93.2--100)**    **(97.2--100)**   **(93.2--100)**   **(97.2--100)**    **(59.0--84.4)**   **(83.4--94.5)**   **(60.4--85.7)**   **(82.6--94.0)**

  *S. anginosus*         29                       100\                            100\                      100\                      100\               100\               100\              100\              100\               100\               91.5\              69.1\              100\
                                                  (88.1--100)                     (97.6--100)               (88.1--100)               (97.6--100)        (88.1--100)        (97.6--100)       (88.1--100)       (97.6--100)        (88.1--100)        (85.8--95.4)       (52.9--82.4)       (97.4--100)

  *S. constellatus*      19                       100\                            100\                      100\                      100\               100\               100\              100\              100\               26.3\              100\               100\               92.1\
                                                  (82.4--100)                     (97.8--100)               (82.4--100)               (97.8--100)        (82.4--100)        (97.8--100)       (82.4--100)       (97.8--100)        (9.2--51.2)        (97.8--100)        (47.8--100)        (87.0--95.6)

  *S. intermedius*       4                        100\                            100\                      100\                      100\               100\               100\              100\              100\               100\               100\               100\               100\
                                                  (39.8--100)                     (97.9--100)               (39.8--100)               (97.9--100)        (39.8--100)        (97.9--100)       (39.8--100)       (97.9--100)        (39.8--100)        (97.9--100)        (39.8--100)        (97.9--100)

  **Sanguinis group**    **12**                   **100**\                        **100**\                  **100**\                  **100**\           **100**\           **100**\          **100**\          **100**\           **91.7**\          **100**\           **100**\           **99.4**\
                                                  **(73.5--100)**                 **(97.8--100)**           **(73.5--100)**           **(97.8--100)**    **(73.5--100)**    **(97.8--100)**   **(73.5--100)**   **(97.8--100)**    **(61.5--99.8)**   **(97.8--100)**    **(71.5--100)**    **(96.8--100)**

  *S. sanguinis*         8                        100\                            100\                      100\                      100\               100\               100\              100\              100\               87.5\              100\               100\               99.4\
                                                  (63.1--100)                     (97.9--100)               (63.1--100)               (97.9--100)        (63.1--100)        (97.9--100)       (63.1--100)       (97.9--100)        (47.4--99.7)       (97.9--100)        (59.0--100)        (96.8--100)

  *S. gordonii*          4                        100\                            100\                      100\                      100\               100\               100\              100\              100\               100\               100\               100\               100\
                                                  (39.8--100)                     (97.9--100)               (39.8--100)               (97.9--100)        (39.8--100)        (97.9--100)       (39.8--100)       (97.9--100)        (39.8--100)        (97.9--100)        (39.8--100)        (97.9--100)

  **Salivarius group**   **2**                    **100**\                        **100**\                  **100**\                  **100**\           **100**\           **100**\          **100**\          **100**\           **100**\           **100**\           **100**\           **100**\
                                                  **(15.8--100)**                 **(98.0--100)**           **(15.8--100)**           **(98.0--100)**    **(15.8--100)**    **(98.0--100)**   **(15.8--100)**   **(98.0--100)**    **(15.8--100)**    **(98.0--100)**    **(15.8--100)**    **(98.0--100)**

  *S. salivarius*        2                        100\                            100\                      100\                      100\               100\               100\              100\              100\               100\               100\               100\               100\
                                                  (15.8--100)                     (98.0--100)               (15.8--100)               (98.0--100)        (15.8--100)        (98.0--100)       (15.8--100)       (98.0--100)        (15.8--100)        (98.0--100)        (15.8--100)        (98.0--100)

  **Bovis group**        **8**                    **100**\                        **100**\                  **100**\                  **100**\           **87.5**\          **100**\          **100**\          **99.4**\          **25.0**\          **100**\           **100**\           **96.7**\
                                                  **(63.1--100)**                 **(97.9--100)**           **(63.1--100)**           **(97.9--100)**    **(47.4--99.7)**   **(97.9--100)**   **(59.0--100)**   **(96.8--100)**    **(3.2--65.1)**    **(97.9--100)**    **(15.8--100)**    **(92.9--98.8)**

  *S. lutetiensis*       2                        100\                            100\                      100\                      100\               100\               100\              100\              100\               0.0\               100\               IC                 98.9\
                                                  (15.8--100)                     (98.0--100)               (15.8--100)               (98.0--100)        (15.8--100)        (98.0--100)       (15.8--100)       (98.0--100)        (0.0--84.2)        (98.0--100)                           (96.1--99.9)

  *S. gallolyticus*      6                        100\                            100\                      100\                      100\               83.3\              100\              100\              99.4\              33.3\              100\               100\               97.8\
                                                  (54.1--100)                     (97.9--100)               (54.1--100)               (97.9--100)        (35.9--99.6)       (97.9--100)       (47.8--100)       (96.8--100)        (4.3--77.7)        (97.9--100)        (15.8--100)        (94.4--99.4)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value, IC, incalculable*.

*Group values of Se, Sp, PPV and NPV are in bold formats*.

Compared with Bruker Biotyper, Vitek MS IVD gave a better resolution for *S. mitis*/*S. oralis* identification with a sensitivity of 100% (95 CI: 75.3--100%) though the two species couldn\'t be distinguished from each other due to database limitation. Similarly, the overall sensitivity for *S. pseudopneumoniae* identification \[77.8% (95 CI: 40.0--97.2%)\] was higher than that of Bruker Biotyper \[11.1% (95 CI: 0.3--48.3%)\].

Expectedly, Vitek MS RUO showed low sensitivity for the identification of most species, except for *S. anginosus, S. intermedius, S. sanguinis, S. gordonii*, and *S. salivarius*.

Discussion {#s4}
==========

Currently, only three studies have compared the performance of Bruker Biotyper vs. Vitek MS for VGS identification, with two of the studies analyzing a limited number of blood culture isolates (Karpanoja et al., [@B15]; Angeletti et al., [@B1]; Isaksson et al., [@B14]). In two of the studies, 16S rRNA gene and *rpoB* gene sequencing were used as a gold standard, while the third study didn\'t have a gold standard. Although the species/group distributions were different in each of these three studies, they all concluded that apart from the misidentification of other species as *S. pneumoniae* by Bruker Biotyper, the MALDI-TOF technique offers a reliable, rapid and cost saving method for VGS identification.

We evaluated the performance of two MALDI-TOF MS systems in VGS identification with a larger number of VGS species and a wider sample type base, using a combination of 16S rRNA gene and *gyrB* sequencing as a gold standard. Overall, the Vitek MS IVD system performed better than the Bruker Biotyper, accurately identifying 98.9% of the 181 VGS isolates, compared to 88.4% for Bruker Biotyper (*P* \< 0.05). The lower overall performance of the Bruker Biotyper MS was due to misidentification of species within the mitis group, with 21 non-pneumococcal isolates misidentified as *S. pneumoniae*, which is in agreement with previous studies (Ikryannikova et al., [@B12], [@B11]; Lopez Roa et al., [@B18]). Notably, we evaluated for the first time, the performance of Vitek MS RUO system though the results were not satisfying. However, this database covers rare VGS species not included in the Vitek MS IVD system (Karpanoja et al., [@B15]).

The superior performance of Vitek MS IVD in distinguishing *S. pneumoniae* from other mitis group species may be due to use of bin-weighting algorithms in species identification. The system identifies significant peaks of sample isolates and divides them into bins that are weighted according to frequency within a given species. Then the sums of bin weights are calculated using the advanced spectrum classifier algorithm to determine the best match, which may enhance sensitivity (Rychert et al., [@B24]). In contrast, Bruker Biotyper uses a single reference strain to generate multiple spectra and chooses a consensus spectra based on the reference spectra. After this, matching signals of the sample spectra are compared to the reference spectra and a score value is created (Welker, [@B31]).

Based on our findings, we designed an identification algorithm for the best way to identify species within the VGS group (Figure [2](#F2){ref-type="fig"}). Laboratories with either of the instruments could refer to this algorithm easily. For Bruker Biotyper MS system, strains with identification scores \<1.7 must be re-tested since VGS are very homologous species. Any identification of *S. pneumoniae* even with a score of \>2.0, should be discounted, optochin test and gene-based analysis need to be performed for confirmation. For Vitek MS, initial identification results with a confidence value \<99.9% for a single result or with multiple/no identification results, must be repeated. If the repeat analysis fails to provide a high confidence value, these isolates should be identified by molecular methods.

![**An identification testing algorithm for viridans group streptococci (VGS) based on the Bruker Biotyper MS system/Vitek MS system and selective molecular identification (see Supplementary Tables [S3](#SM3){ref-type="supplementary-material"} and [S4](#SM4){ref-type="supplementary-material"})**.\
^*a*^For Bruker Biotyper MS system, strains with identification scores \<1.7 must be re-tested.\
^*b*^Any identification of *S. pneumoniae* even with a score of \>2.0, should be preliminatory and then do further sequencing for the high incorrect identification rate.\
Gene-based analysis confirmed that 85 out of the 106 isolates were *S. pneumoniae* while the rest are non-*S. pneumoniae* (Supplementary Table [S3](#SM3){ref-type="supplementary-material"}).\
^*c*^For Vitek MS, initial identification results with a confidence value \<99.9% for a single isolate or with multiple/no identification results, must be repeated (Supplementary Table [S4](#SM4){ref-type="supplementary-material"}).](fmicb-07-01328-g0002){#F2}

Study limitations include possible selection bias as isolates were from a single center, imbalance in group/species distribution of isolates, with some groups and species poorly represented, e.g., the bovis and salivarius groups. And finally, for uniformity, protein extraction step was not performed for all assays.

Summary {#s5}
=======

This study shows that both the Bruker Biotyper and the Vitek MS IVD systems can provide a good alternative to phenotypic methods for VGS identification. However, further improvements in the data bases are needed to increase the identification accuracy. In the mean-time, gene-based sequencing remains the best way to correctly identify VGS species. The proposed integrated algorithm is a practical approach in VGS identification at this stage.
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MALDI-TOF

:   matrix-assisted laser desorption ionization-time of flight

VGS

:   viridans group streptococci

MLSA

:   multilocus sequence analysis

PUMCH

:   Peking Union Medical College Hospital
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:   *In Vitro* Diagnosis
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CI

:   confidence interval

PPV

:   positive predictive value

NPV

:   negative predictive value
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